Cystic Fibrosis Market Research Report- Global Forecast till 2022

Cystic Fibrosis Market Research Report- Global Forecast till 2022

ID: MRFR/HC/1293-CRR | November, 2017 | Region: Global | 85 pages | Cooked Research Reports

Global Cystic Fibrosis Market Information: By Treatment Method (Medication, Devices, And Other Treatments) - Global Forecast Till 2022



Market Scenario
Cystic fibrosis (CF) is a chronic, genetic disease which affects the overall progress of entire body leading to severe disability and early death in many cases. CF is mainly caused due to several mutations in the gene which encodes for cystic fibrosis transmembrane conductance regulator (CFTR) protein. According to the Cystic Fibrosis foundation (CFF), currently there are approximately 70,000 people who are suffering from cystic fibrosis worldwide.


Chest Physical Therapy (CPT) is a technique which is mainly done in cases of cystic fibrosis to drain out the mucus out of the body. In CPT, patient uses gravity to pull out the mucus by getting into different positions. While the patient is lying, the caretaker or the medical nurse taps or vibrates the chest of the patient in order to dislodge the thick mucus inside the lungs.


Development of new drugs and therapies, and financial support from CFF in research and development of CF drugs are the key drivers fueling the growth of the market. In 2015, CFF announced a grants of $23 Million to 11 cystic fibrosis research and development centers in the United States. In total, CFF has invested around $425 Million in order to boost the drug development for this disorder. The constant financial support from the foundation encourages the biopharmaceutical companies to involve in the research of rare disease leading to the development of novel drugs. Despite these drivers, high cost of the drugs and treatment may hamper the growth of the market. The two most effective drug treatments for cystic fibrosis come with huge price tags, Kalydeco ($311,000/year) and Orkambi ($259,000/year). These high prices makes the CF treatment unaffordable for most of the patients.


It is estimated that cystic fibrosis market is expected to grow at a CAGR of 13.5% during the forecast period 2016-2022.


 


Intended Audience



  • Cystic fibrosis manufacturers & suppliers

  • Contract Research Organizations (CROs)

  • Research and Development (R&D) Companies

  • Government Research Laboratories

  • Independent Research Laboratories

  • Government and Independent Regulatory Authorities

  • Market Research and Consulting Service Providers

  • Academic Institutes and Universities



Figure: Global Cystic Fibrosis Market, By Region, 2015 (%)

Global Cystic Fibrosis Market


Sources: Annual reports, Press release, White paper, Company presentation


 


Segmentation


The global cystic fibrosis market is segmented on the basis of treatment method. Treatment method is further segmented into medication, devices, and other treatments.


 


Key Findings



  • The global cystic fibrosis market is expected to reach USD 1,192.2 million by 2022 at a CAGR of 13.8%

  • On the basis of treatment method, medication market is expected to command the largest market share of 76.4% over the review period and it is also expected to grow at the fastest CAGR of 14% during the forecast period 2016-2022

  • The North America hold the largest share of the cystic fibrosis market and is expected to reach USD 521.0 million by 2022

  • Europe is the fastest growing market, which is expected to grow at a CAGR of 14.1% over the 2017-2023


 


Regional Analysis
The North America dominates the cystic fibrosis market owing to the high incidence rate of cystic fibrosis. According to cystic fibrosis foundation, more than 30,000 patients are living with cystic fibrosis in the U.S. and nearly, 1000 new cystic fibrosis cases are diagnosed each year. According to CFF’s national patient registry, the median age of the person with cystic fibrosis is currently 33.4 years.


European region stands second in the regions affected by cystic fibrosis. According to the European Cystic Fibrosis Society (ECFS), considering the 26 major countries in Europe, more than 35,500 people were suffering from cystic fibrosis in 2014. Among the CF patients in Europe, 51.8% were adults with age 18 years or more and 48.2% were less than 18 years old. Countries like the United Kingdom, Ireland, Romania, and Bulgaria have higher birth prevalence of CF.


The prevalence of cystic fibrosis is seen to be very low in the Asian region. The exact prevalence is not known but the risk of child birth with cystic fibrosis in Asian people is 1 in 100,000. The prevalence of CF is rare in the East Asian countries like China and Japan.


The Middle East and Africa holds the least share in the market owing to the presence of poor and slow developing countries, especially countries in the African region.



Key Players
Some of the key players in this market are Vertex Pharmaceuticals, F. Hoffmann-La Roche, AbbVie, Gilead Sciences, Novartis, Genentech, Pharmaxis, Chiesi Farmaceutici, Forest Laboratories and others.      
  


Research Methodology


Global Cystic Fibrosis Market-


Sources: Annual reports, Press release, White paper, and Company presentation




License

Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency

TABLE OF CONTENTS

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.3 MARKET STRUCTURE:

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5.1 IMMUNOREACTIVE TRYPSINOGEN (IRT) TEST

5.2 SWEAT CHLORIDE TEST

5.3 SPUTUM TEST

5.4 CHEST X-RAY

5.5 CT SCAN

5.6 PULMONARY FUNCTION TEST

6.1 MEDICAL THERAPY

6.2 SURGICAL TREATMENT

6.3 OTHERS

8.1 NORTH AMERICA

8.1.1 INTRODUCTION

8.2 EUROPE

8.2.1 INTRODUCTION

8.3 ASIA-PACIFIC

8.3.1 INTRODUCTION

8.4 MIDDLE EAST & AFRICA

8.4.1 INTRODUCTION

9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

9.1.1 STRATEGIC PARTNERSHIP

9.1.2 MERGER & ACQUISITION

10.1 ABBVIE

10.1.1 OVERVIEW

10.1.2 PRODUCT OVERVIEW

10.1.3 FINANCIALS

10.1.4 KEY DEVELOPMENTS

10.2 CHIESI FARMACEUTICI

10.2.1 OVERVIEW

10.2.2 PRODUCT OVERVIEW

10.2.3 FINANCIALS

10.2.4 KEY DEVELOPMENTS

10.3 F. HOFFMANN-LA ROCHE

10.3.1 OVERVIEW

10.3.2 PRODUCT OVERVIEW

10.3.3 FINANCIALS

10.3.4 STRATEGY

10.3.5 KEY DEVELOPMENT

10.4 FOREST LABORATORIES

10.4.1 OVERVIEW

10.4.2 PRODUCT OVERVIEW

10.4.3 FINANCIALS

10.4.4 KEY DEVELOPMENTS

10.5 GENENTECH

10.5.1 OVERVIEW

10.5.2 PRODUCT OVERVIEW

10.5.3 FINANCIALS

10.5.4 KEY DEVELOPMENTS

10.6 GILEAD SCIENCES

10.6.1 OVERVIEW

10.6.2 PRODUCT OVERVIEW

10.6.3 FINANCIALS

10.6.4 STRATEGY

10.6.5 KEY DEVELOPMENTS

10.7 NOVARTIS

10.7.1 OVERVIEW

10.7.2 PRODUCT OVERVIEW

10.7.3 FINANCIALS

10.7.4 STRATEGY

10.7.5 KEY DEVELOPMENTS

10.8 PHARMAXIS

10.8.1 OVERVIEW

10.8.2 PRODUCT OVERVIEW

10.8.3 FINANCIAL

10.8.4 KEY DEVELOPMENTS

10.9 VERTEX PHARMACEUTICALS

10.9.1 OVERVIEW

10.9.2 PRODUCT OVERVIEW

10.9.3 FINANCIALS

10.9.4 KEY DEVELOPMENTS

10.10 OTHERS


TABLE 1 GLOBAL CYSTIC FIBROSIS MARKET, BY DIAGNOSTIC TEST, 2013-2022 (USD MILLION)

TABLE 2 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT, 2013-2022 (USD MILLION)

TABLE 3 GLOBAL CYSTIC FIBROSIS MARKET, BY DRUG TYPE, 2013-2022 (USD MILLION)

TABLE 4 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2013-2022 (USD MILLION)


FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL CYSTIC FIBROSIS MARKET, BY DIAGNOSTIC TEST

FIGURE 4 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT

FIGURE 5 GLOBAL CYSTIC FIBROSIS MARKET, BY DRUG TYPE

FIGURE 6 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION

FIGURE 7 GLOBAL CYSTIC FIBROSIS MARKET: COMPANY SHARE ANALYSIS, 2015 (%)